Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2

Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2

Fixed antidiabetic drugs’ combinations have aim to improve of Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control of fasting and prandial glucose levels, contained insulin glargine 100 UI/ml and lixisenatide. In the...

Full description

Bibliographic Details
Main Authors:	S. К. Zyryanov, I. N. Dyakov
Format:	Article
Language:	Russian
Published:	Izdatelstvo OKI 2019-01-01
Series:	Качественная клиническая практика
Subjects:	health technology assessment diabetes mellitus type 2 insulin glargine lixisenatide
Online Access:	https://www.clinvest.ru/jour/article/view/413

Similar Items

Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
by: S. V. Nedogoda, et al.
Published: (2020-01-01)

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide
by: M. V. Martjanova, et al.
Published: (2020-05-01)

Economic perspectives for effective control of diabetes mellitus type 2 with fixed combination of basal insulin analog and GLP-1 agonist
by: S. K. Zyryanov, et al.
Published: (2019-10-01)

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020-05-01)

Economic evaluation of insulin therapy intensification for effective and safe control of diabetes mellitus type 2
by: A. S. Kolbin, et al.
Published: (2019-10-01)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
by: Lau IT, et al.
Published: (2017-06-01)

Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)
by: Ivona Renata Yarek-Martynova, et al.
Published: (2011-12-01)

Clinical experience in using long-acting human insulin Glargine 300 U/ml in the practice of an endocrinologist
by: O. A. Guseva, et al.
Published: (2018-04-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Intensive Insulin Titration with Insulin Glargine in Insulin-Naive Type 2 Diabetic Patients in Turkey: LANTIT Study
by: Ercan Tuncel, et al.
Published: (2015-09-01)

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
by: Yu Mi Kang, et al.
Published: (2019-08-01)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
by: Kai‐Jen Tien, et al.
Published: (2019-05-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
by: Fournier, Marie, et al.
Published: (2014-10-01)

Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
by: Liu D, et al.
Published: (2021-04-01)

The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel
by: Cheli Melzer Cohen, et al.
Published: (2020-07-01)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
by: Shafie AA, et al.
Published: (2020-06-01)

rDNA insulin glargine U300 – a critical appraisal
by: Wang F, et al.
Published: (2016-12-01)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
by: Xiaoli Sheng, et al.
Published: (2019-08-01)

Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
by: Marina Vladimirovna Shestakova, et al.
Published: (2010-03-01)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
by: Mizuho Yamabe, et al.
Published: (2019-03-01)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
by: Chitrabhanu Ballav, et al.
Published: (2020-07-01)

Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
by: L. N. Shitov, et al.
Published: (2019-04-01)

Insulin glargine use and breast cancer: a systematic review and meta-analysis
by: Ibrahim Altedlawi Albalawi, et al.
Published: (2019-03-01)

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies
by: Bin Sun, et al.
Published: (2021-06-01)

Insulin choice in feline diabetes mellitus
by: Yaiza Gomez Mejias
Published: (2021-08-01)

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
by: Trevor J. Orchard, et al.
Published: (2017-06-01)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
by: Sondra Davis, et al.
Published: (2017-04-01)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
by: Dippel, Franz-Werner, et al.
Published: (2010-01-01)

Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives
by: de Galan BE
Published: (2016-10-01)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019-11-01)

Effect of insulin glargine on glycemic control in adolescents with type 1-diabetes
by: Hassan M. Mona, et al.
Published: (2015-06-01)

Development and Validation of Approach for the Detection of Neutralizing Antibodies Against Insulin (Glargine) in Human Blood Plasma
by: N. B. Abramenko, et al.
Published: (2019-09-01)

Insulin glargine affects the expression of Igf-1r, Insr, and Igf-1 genes in colon and liver of diabetic rats
by: Clara I Juárez-Vázquez, et al.
Published: (2018-05-01)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
by: Jakobsen Marie, et al.
Published: (2012-09-01)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
by: Thomann R, et al.
Published: (2020-07-01)

Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen
by: N V Efremova, et al.
Published: (2015-10-01)

The economic prognosis of the new analog of insulin glargine usage in diabetes mellitus type 2
by: D. Yu. Belousov, et al.
Published: (2018-05-01)

Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
by: Nader ND, et al.
Published: (2020-03-01)

Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control – a prospective cohort study
by: Jing Li, et al.
Published: (2018-10-01)

Cannot write session to /tmp/vufind_sessions/sess_rb3vbiust9v2h82lbos29guh3a